TY - JOUR
T1 - Chitosan surface modified PLGA nanoparticles loaded with brigatinib for the treatment of non-small cell lung cancer
AU - Mohammed, Muqtader
AU - Alnafisah, Mansour S.
AU - Anwer, Md Khalid
AU - Fatima, Farhat
AU - Almutairy, Bjad K.
AU - Alshahrani, Saad M.
AU - Alshetaili, Abdullah S.
AU - Alalaiwe, Ahmed
AU - Fayed, Mohamed H.
AU - Alanazi, Ahmad Z.
AU - Al Zahrani, Mohammed
AU - Hailat, Mohammad M.
AU - Al-Shdefat, Ramadan
N1 - Publisher Copyright:
© 2019 Walter de Gruyter GmbH. All rights reserved.
PY - 2019
Y1 - 2019
N2 - In the current study, surface-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) of brigatinib (BRB) were prepared by studying the variables PLGA (polymer), PVA (stabilizer) and chitosan (coater) against experimentally obtained responses. The optimized NPs (F2) were evaluated in vitro for differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), particle size, polydispersity index (PDI) and drug entrapment (EE), in vitro release, hematocompatibility and in vitro anticancer studies. The optimized NPs’ (F2) composition, PLGA (75 mg), PVA (0.55% w/v), chitosan (0.75% w/v) and 30 mg of BRB was found to be optimum with particle size (406.3 ± 5.1 nm), PDI (0.277), ζ potential (30.4 ± 3.3 mV) and %EE (82.32%). The in vitro release profile showed a sustained release pattern of the F2 nanoparticles of BRB. The 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay revealed a significant anticancer activity for F2 NPs against A549 cell lines in comparison to free BRB. The result obtained in this work indicated the immense potential of nanoparticles to effectively deliver the BRB to the cancer site for the treatment of non-small cell lung cancer.
AB - In the current study, surface-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) of brigatinib (BRB) were prepared by studying the variables PLGA (polymer), PVA (stabilizer) and chitosan (coater) against experimentally obtained responses. The optimized NPs (F2) were evaluated in vitro for differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), X-ray diffraction (XRD), scanning electron microscopy (SEM), particle size, polydispersity index (PDI) and drug entrapment (EE), in vitro release, hematocompatibility and in vitro anticancer studies. The optimized NPs’ (F2) composition, PLGA (75 mg), PVA (0.55% w/v), chitosan (0.75% w/v) and 30 mg of BRB was found to be optimum with particle size (406.3 ± 5.1 nm), PDI (0.277), ζ potential (30.4 ± 3.3 mV) and %EE (82.32%). The in vitro release profile showed a sustained release pattern of the F2 nanoparticles of BRB. The 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay revealed a significant anticancer activity for F2 NPs against A549 cell lines in comparison to free BRB. The result obtained in this work indicated the immense potential of nanoparticles to effectively deliver the BRB to the cancer site for the treatment of non-small cell lung cancer.
KW - A549 cell lines
KW - brigatinib
KW - hemocompatibility
KW - nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85074252657&partnerID=8YFLogxK
U2 - 10.1515/polyeng-2019-0265
DO - 10.1515/polyeng-2019-0265
M3 - Article
AN - SCOPUS:85074252657
SN - 0334-6447
VL - 39
SP - 909
EP - 916
JO - Journal of Polymer Engineering
JF - Journal of Polymer Engineering
IS - 10
ER -
